Research report published today:
"Telix Pharmaceuticals has added significant value by acquiring ANMI, the developer of its TLX591-CDx prostate cancer imaging kit and underlying ‘cold kit’ technology. It also announced plans to accelerate its TLX591 prostate cancer therapeutic into Phase III, based on a third-party review of clinical data that formed part of the Atlab acquisition in September. Following the ANMI acquisition we increase our valuation to A$380m (vs A$303m) or A$1.74 per share (vs A$1.43 per share). FDA agreement to the TLX591 Phase III design would likely prompt a further valuation uplift..."
New Research Report: Edison Group
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.97 |
Change
-0.080(0.53%) |
Mkt cap ! $4.946B | |||
| Open | High | Low | Value | Volume |
| $15.25 | $15.37 | $14.71 | $14.77M | 987.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1576 | $14.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.98 | 5576 | 2 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$14.89 |
Change
-0.080 ( 1.01 %) |
||||
| Open | High | Low | Volume | ||
| $15.27 | $15.36 | $14.72 | 134334 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| TLX (ASX) Chart |